Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves

TheMotleyFool

0 0

After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves: https://g.foolcdn.com/editorial/images/771097/doctor-patient-check-up-blood-pressure-pulse.jpg

Diabetes and obesity care are two engines fueling the pharmaceutical industry right now. Novo Nordisk (NYSE: NVO) is at the forefront of these markets thanks to its red-hot blockbuster drugs Ozempic, Rybelsus, and Wegovy.

2024 has been a milestone year for Novo Nordisk, and the momentum doesn't appear to be slowing down. Let's dig into the company's latest wins and assess if now is a good time to scoop up some shares.

Oftentimes, pharmaceutical companies will seek alternative uses for their most successful medications. These are known as expanded indications; they go through a separate and robust clinical-trial process with the Food and Drug Administration (FDA).

Source Fool.com

Like: 0

NVO

Share